Abstract
While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.
Original language | English (US) |
---|---|
Pages (from-to) | 6018-6020 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 25 |
Issue number | 20 |
DOIs | |
State | Published - Oct 15 2019 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Twist of fate for acute promyelocytic leukemia : Trib3–TwIst1 interaction promotes resistance. / Peeke, Stephen Z.; Gritsman, Kira.
In: Clinical Cancer Research, Vol. 25, No. 20, 15.10.2019, p. 6018-6020.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Twist of fate for acute promyelocytic leukemia
T2 - Trib3–TwIst1 interaction promotes resistance
AU - Peeke, Stephen Z.
AU - Gritsman, Kira
PY - 2019/10/15
Y1 - 2019/10/15
N2 - While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.
AB - While acute promyelocytic leukemia has a good prognosis with all-trans retinoic acid (ATRA) treatment, ATRA resistance is a major obstacle. It is now demonstrated that TRIBBLES 3 (TRIB3) stabilizes TWIST1, leading to ATRA resistance. Peptides that disrupt this interaction lead to the degradation of TWIST1 and overcome ATRA resistance.
UR - http://www.scopus.com/inward/record.url?scp=85073307158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073307158&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-2140
DO - 10.1158/1078-0432.CCR-19-2140
M3 - Article
C2 - 31405833
AN - SCOPUS:85073307158
VL - 25
SP - 6018
EP - 6020
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 20
ER -